Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An experimental platform for systemic drug delivery to the retina

12 Oct 2009

Abstract excerpt

Degenerative retinopathies, including age-related macular degeneration, diabetic retinopathy, and hereditary retinal disorders--major causes of world blindness--are potentially treatable by using low-molecular weight neuroprotective, antiapoptotic, or antineovascular drugs. These agents are, however, not in current systemic use owing to, among other factors, their inability to passively diffuse across the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Barrier Structure and Function Studies
Share to Retinal Development and Disorders
Share to Retinal Diseases and Treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19822744
DOI: 10.1073/pnas.0908561106

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 27 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An experimental platform for systemic drug delivery to the retinaPMID 19822744Read ↗

Ocular delivery of different VCP inhibitory formulations prevents retinal degeneration in rhodopsin 255 isoleucine deletion miceSemantic proximity Read ↗

miR-181a/b downregulation: a mutation-independent therapeutic approach for inherited retinal diseases.Semantic proximity Read ↗

Self-assembled nanoparticles enable delivery of VCP inhibitor, resulting in enhanced photoreceptor protection in retinal explantsSemantic proximity Read ↗

Non-antibiotic Small-Molecule Regulation of DHFR-Based Destabilizing Domains In VivoSemantic proximity Read ↗

Design and Application of a μSiM Outer Blood-Retinal Barrier (OBRB) Model as a Drug Development ToolSemantic proximity Read ↗

Recombinant protein delivery enables modulation of the phototransduction cascade in mouse retinaSemantic proximity Read ↗

Therapeutic benefit derived from RNAi-mediated ablation of IMPDH1 transcripts in a murine model of autosomal dominant retinitis pigmentosa (RP10).Semantic proximity Read ↗

Idebenone protects against retinal damage and loss of vision in a mouse model of Leber's hereditary optic neuropathy.Semantic proximity Read ↗

A novel multiplex RNAi therapy simultaneously targets <i>Hif1a</i> and <i>Hif2a</i> to defy retinal degeneration in two models of AMDSemantic proximity Read ↗

Protection of photoreceptors in a mouse model of RP10.Semantic proximity Read ↗

Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa.Semantic proximity Read ↗

Topical Eyedrop of 4-Hydroxytamoxifen Enables Cre-Mediated Gene Editing in OligodendrocytesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.